NCT06019000

Study of CYR-064 Versus Placebo in Patients.

A Randomized, Double-Blinded, Placebo-Controlled Trial to Determine The Safety and Efficacy of CYR-064

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 151 (actual)
• Sponsor: Cyrano Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.

Detailed description

The purpose of this study is to determine the safety and effectiveness of CYR-064 in a randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR064. The study will take approximately 32 weeks which will include a 4-week screening period to evaluate if participants are right for the Study, followed by a 24-week Treatment Period, and a 1 week follow up after participants have completed the Study. About 150 subjects will participate in this study in about 25 research sites in the United States.

Conditions

• Hyposmia

Interventions

Type	Name	Description
COMBINATION_PRODUCT	CYR-064	CYR-064 is a nasal solution.

Timeline

• Start date: 2023-09-26
• Primary completion: 2025-11-11
• Completion: 2025-11-21
• First posted: 2023-08-31
• Last updated: 2026-02-18

Locations

14 sites across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study